Cofactor Genomics

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Cofactor Genomics sits in the upper half of US sponsors by registered trial count (#7,388 of 15,742 sponsors by registered trial count).

1 total trials 1 currently recruiting upper half by trial count

Cofactor Genomics: 1 sponsored US clinical trial, 1 recruiting.

Cofactor Genomics sponsors 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting. The most-studied condition in this pipeline is Cancer of Head and Neck, with 1 trials.

Mid-pack sponsor footprint

Cofactor Genomics is in the upper half of sponsors by trial count (#7,388 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

Open and recent trials

1 total, page 1 of 1

RECRUITING

A Multicenter Cancer Biospecimen Collection Study

NCT04510129

Therapeutic Areas

Cancer of Head and Neck 1
Lung Cancer, Non-Small Cell 1
Gastroesophageal Junction Adenocarcinoma 1
Cervical Cancer 1
Esophageal Squamous Cell Carcinoma 1
Hepatocellular Carcinoma 1
Small-cell Lung Cancer 1
Triple Negative Breast Cancer 1
Renal Cell Carcinoma 1
Urothelial Carcinoma 1

What is open in the Cofactor Genomics pipeline

1 recruiting of 1 indexed (100% open).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Cancer of Head and Neck (1 trial), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Cofactor Genomics: open-pipeline peers nationwide

Peers matched on 1 registered trials and 100% open enrollment, not the therapeutic-area sidebar.

Cofactor Genomics sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 012345 0%50%100%150% Total trials Recruiting share Cofactor Genomics1200 Pharma1ST Biotherapeutics3 Waves Wellness3EO HealthAAVantgarde Bio SrlAcorn BiolabsAcrivon TherapeuticsADARx Pharmaceuticals
Cofactor Genomics sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Cofactor Genomics sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1 trials (± recruiting share)

Sponsors near 100% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Cofactor Genomics page

1 registered trials is a research-attention snapshot, not an endorsement of Cofactor Genomics or any single study.

  • 1 of Cofactor Genomics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Cancer of Head and Neck is the condition Cofactor Genomics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Cancer of Head and Neck trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Cofactor Genomics pipeline card: 1 registered trials from official public datasets.Report a data error.